Response Biomedical (RPBIF) 0.5450 $RPBIF
Response Biomedical Corp. Announces the Appointment of Dr. Barbara Kinnaird Ph.D. as Chief Executive Officer and Voting Results from its 2015 AGM
Marketwired - Tue May 19, 9:46PM CDT
The Board of Directors of Response Biomedical Corp. (TSX: RBM)(OTCQB: RPBIF) ("Response" or "the Company"
, is pleased to announce the promotion of Dr. Barbara Kinnaird Ph.D. to the position of Chief Executive Officer effective immediately. The Board would like to thank Dr. Anthony (Tony) Holler for his service as Interim Chief Executive Officer since September 2014.
RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Announces First Quarter 2015 Financial Results
Marketwired - Tue May 05, 7:31AM CDT
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCQB: RPBIF) today reported financial results for its first quarter ended March 31, 2015.
RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Schedules First Quarter 2015 Earnings Release and Announces Participation in Upcoming Investor Conference and Annual General Meeting
Marketwired - Thu Apr 23, 4:30PM CDT
Response Biomedical Corp. ("Response" (TSX: RBM)(OTCQB: RPBIF) will release its first quarter 2015 financial results before the markets open on Tuesday May 5, 2015.
RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Announces Achievement of Third Milestone in Co-Development Collaboration
Marketwired - Tue Apr 14, 4:01PM CDT
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCQB: RPBIF) today announced that it has earned the third milestone of US$360,000 in the Collaboration Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar". The milestone was earned upon the delivery of certain components for the high throughput rapid immunoassay analyzer developed by Joinstar. The companies have entered into definitive Collaboration and Supply Agreements whereby Response and Joinstar will co-develop components and assays for the new analyzer and Response will provide certain materials to Joinstar required for Joinstar to manufacture and sell these assays specifically to run on their new analyzer.
RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2014 Financial Results
Marketwired - Mon Mar 16, 4:01PM CDT
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCQB: RPBIF) today reported financial results for the fourth quarter and year ended December 31, 2014.
RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Schedules Fourth Quarter and Fiscal Year 2014 Earnings Release and Conference Call
Marketwired - Thu Mar 12, 5:52PM CDT
Response Biomedical Corp. ("Response" (TSX: RBM)(OTCQB: RPBIF) will release its fourth quarter and fiscal year 2014 financial results after the markets close on Monday, March 16, 2015.
RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Announces Milestone Achievement in Co-Development Collaboration
Marketwired - Mon Feb 16, 7:09PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCQB: RPBIF) today announced that it has earned the second milestone of US$720,000 in the funded Technology Development Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar". The milestone was earned upon the signing of the definitive Collaboration Agreement to support the co-development by Response and Joinstar of components and assays that will run on a high throughput rapid immunoassay analyzer developed by Joinstar. Concurrently, the companies have entered into a definitive Supply Agreement whereby Response will provide certain materials to Joinstar required for Joinstar to manufacture and sell these assays specifically to run on their new analyzer.
RBM.TO: 0.99 (+0.07)
Week In Review: Cellular Biomedicine In-Licenses Cancer Immunotherapy From China
ChinaBio Today - at Seeking Alpha - Sun Feb 15, 10:14AM CST
Deals and Financings Cellular Biomedicine Group (NASDAQ: CBMG ), a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing (see story ). The two groups will...
NVO: 57.68 (+2.91), MRK: 57.95 (+0.57), QGEN: 25.73 (+1.00), CBMG: 29.80 (+0.31)
Response Biomedical Corp. Announces Expansion of Chinese Distribution Agreement for RAMP(R) Cardiovascular Products
Marketwired - Fri Feb 06, 5:56PM CST
Response Biomedical Corp. ("Response" or the "Company" (TSX: RBM)(OTCQB: RPBIF) today announced that it has expanded the scope of its agreement to distribute its Cardiovascular portfolio of RAMP(R) products with Shanghai Elite Biotech Co., Ltd. ("Shanghai Elite". Effective April 23, 2015, Shanghai Elite will become the exclusive national distributor in China for Response's RAMP(R) branded cardiovascular Point of Care Testing ("POCT" portfolio.
RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Renegotiates Term Loan with Silicon Valley Bank
Marketwired - Mon Dec 15, 4:23PM CST
Response Biomedical Corp. ("Response" or "the Company" (TSX: RBM)(OTCBB: RPBIF) announced that the Company has entered into an Amendment to its existing Loan Agreement (the "Amended Loan Agreement" with the lender under its outstanding term loan, Silicon Valley Bank ("SVB", as of December 15, 2014. Under the terms of the Amended Loan Agreement, SVB has agreed to continue to advance the remaining outstanding principal of US$1,359,375 for the same term and interest rate, waive its rights in respect of the previously announced breaches of certain financial covenants and to remove any future minimum revenue and liquidity ratio financial covenants. SVB will receive additional warrants and a final payment of up to 4% of the principal advanced.
RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Announces Closing of Private Placement
Marketwired - Fri Dec 12, 12:49PM CST
Response Biomedical Corp. ("Response" or the "Company" (TSX: RBM)(OTCBB: RPBIF) is pleased to announce the closing of the previously announced non-brokered private placement (the "Private Placement" with two entities related to Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar" for 1,800,000 common shares of Response at a price of $1.21 per share for total gross proceeds of $2,178,000.
RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Announces the Appointment of Dr. Barbara Kinnaird Ph.D. as Chief Executive Officer and Voting Results from its 2015 AGM
Marketwired - Tue May 19, 9:46PM CDT
The Board of Directors of Response Biomedical Corp. (TSX: RBM)(OTCQB: RPBIF) ("Response" or "the Company"
, is pleased to announce the promotion of Dr. Barbara Kinnaird Ph.D. to the position of Chief Executive Officer effective immediately. The Board would like to thank Dr. Anthony (Tony) Holler for his service as Interim Chief Executive Officer since September 2014. RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Announces First Quarter 2015 Financial Results
Marketwired - Tue May 05, 7:31AM CDT
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCQB: RPBIF) today reported financial results for its first quarter ended March 31, 2015. RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Schedules First Quarter 2015 Earnings Release and Announces Participation in Upcoming Investor Conference and Annual General Meeting
Marketwired - Thu Apr 23, 4:30PM CDT
Response Biomedical Corp. ("Response"
(TSX: RBM)(OTCQB: RPBIF) will release its first quarter 2015 financial results before the markets open on Tuesday May 5, 2015. RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Announces Achievement of Third Milestone in Co-Development Collaboration
Marketwired - Tue Apr 14, 4:01PM CDT
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCQB: RPBIF) today announced that it has earned the third milestone of US$360,000 in the Collaboration Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar". The milestone was earned upon the delivery of certain components for the high throughput rapid immunoassay analyzer developed by Joinstar. The companies have entered into definitive Collaboration and Supply Agreements whereby Response and Joinstar will co-develop components and assays for the new analyzer and Response will provide certain materials to Joinstar required for Joinstar to manufacture and sell these assays specifically to run on their new analyzer. RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Announces Fourth Quarter and Fiscal 2014 Financial Results
Marketwired - Mon Mar 16, 4:01PM CDT
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCQB: RPBIF) today reported financial results for the fourth quarter and year ended December 31, 2014. RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Schedules Fourth Quarter and Fiscal Year 2014 Earnings Release and Conference Call
Marketwired - Thu Mar 12, 5:52PM CDT
Response Biomedical Corp. ("Response"
(TSX: RBM)(OTCQB: RPBIF) will release its fourth quarter and fiscal year 2014 financial results after the markets close on Monday, March 16, 2015. RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Announces Milestone Achievement in Co-Development Collaboration
Marketwired - Mon Feb 16, 7:09PM CST
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCQB: RPBIF) today announced that it has earned the second milestone of US$720,000 in the funded Technology Development Agreement with Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar". The milestone was earned upon the signing of the definitive Collaboration Agreement to support the co-development by Response and Joinstar of components and assays that will run on a high throughput rapid immunoassay analyzer developed by Joinstar. Concurrently, the companies have entered into a definitive Supply Agreement whereby Response will provide certain materials to Joinstar required for Joinstar to manufacture and sell these assays specifically to run on their new analyzer. RBM.TO: 0.99 (+0.07)
Week In Review: Cellular Biomedicine In-Licenses Cancer Immunotherapy From China
ChinaBio Today - at Seeking Alpha - Sun Feb 15, 10:14AM CST
Deals and Financings Cellular Biomedicine Group (NASDAQ: CBMG ), a China-US cell therapy company, acquired CAR-T cancer immunotherapy technology from the Chinese PLA General Hospital (the 301 hospital) of Beijing (see story ). The two groups will...
NVO: 57.68 (+2.91), MRK: 57.95 (+0.57), QGEN: 25.73 (+1.00), CBMG: 29.80 (+0.31)
Response Biomedical Corp. Announces Expansion of Chinese Distribution Agreement for RAMP(R) Cardiovascular Products
Marketwired - Fri Feb 06, 5:56PM CST
Response Biomedical Corp. ("Response" or the "Company"
(TSX: RBM)(OTCQB: RPBIF) today announced that it has expanded the scope of its agreement to distribute its Cardiovascular portfolio of RAMP(R) products with Shanghai Elite Biotech Co., Ltd. ("Shanghai Elite". Effective April 23, 2015, Shanghai Elite will become the exclusive national distributor in China for Response's RAMP(R) branded cardiovascular Point of Care Testing ("POCT" portfolio. RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Renegotiates Term Loan with Silicon Valley Bank
Marketwired - Mon Dec 15, 4:23PM CST
Response Biomedical Corp. ("Response" or "the Company"
(TSX: RBM)(OTCBB: RPBIF) announced that the Company has entered into an Amendment to its existing Loan Agreement (the "Amended Loan Agreement" with the lender under its outstanding term loan, Silicon Valley Bank ("SVB", as of December 15, 2014. Under the terms of the Amended Loan Agreement, SVB has agreed to continue to advance the remaining outstanding principal of US$1,359,375 for the same term and interest rate, waive its rights in respect of the previously announced breaches of certain financial covenants and to remove any future minimum revenue and liquidity ratio financial covenants. SVB will receive additional warrants and a final payment of up to 4% of the principal advanced. RBM.TO: 0.99 (+0.07)
Response Biomedical Corp. Announces Closing of Private Placement
Marketwired - Fri Dec 12, 12:49PM CST
Response Biomedical Corp. ("Response" or the "Company"
(TSX: RBM)(OTCBB: RPBIF) is pleased to announce the closing of the previously announced non-brokered private placement (the "Private Placement" with two entities related to Hangzhou Joinstar Biomedical Technology Co. Ltd. ("Joinstar" for 1,800,000 common shares of Response at a price of $1.21 per share for total gross proceeds of $2,178,000. RBM.TO: 0.99 (+0.07)
